The above studies suggested that FAM134B may represent an important target for clinical intervention in HCC by controlling JAK2/STAT3 signaling, which gives hope for the further development of this compound as a drug used in HCC clinical oncology. Here, RETREG1 is linked to hepatocellular carcinoma.